• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病和贫血对经皮冠状动脉血运重建术后结局的影响。

Impact of Chronic Kidney Disease and Anemia on Outcomes After Percutaneous Coronary Revascularization.

机构信息

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

出版信息

Am J Cardiol. 2019 Sep 15;124(6):851-856. doi: 10.1016/j.amjcard.2019.06.001. Epub 2019 Jun 11.

DOI:10.1016/j.amjcard.2019.06.001
PMID:31375241
Abstract

Few studies have evaluated outcomes after percutaneous coronary intervention (PCI) in patients with both anemia (hemoglobin < 12 g/dl in women; <13 in men) and chronic kidney disease (CKD, estimated glomerular filtration rate < 60 ml/min/1.73 m). Patients with coronary artery disease who underwent PCI in our health system from 2010 to 2018 were included (n = 10,756), excluding those with ST-elevation myocardial infarction or shock. We evaluated the individual and combined effects of anemia and CKD on outcomes. Five-year mortality was highest in the cohort with both anemia and CKD and lowest in those with neither. After multivariate analysis, with the group with neither anemia nor CKD as a reference, the adjusted hazard ratio for mortality was 1.68 (95% confidence interval [CI] 1.45 to 1.95, p <0.001) for those with anemia alone, 1.33 (95% CI 1.15 to 1.53, p <0.001) for those with CKD alone, and 2.83 (95% CI 2.49 to 3.22, p <0.001) for those with both anemia and CKD. With respect to readmission and reintervention, similar tends were observed, with patients with both CKD and anemia having the highest risk for these outcomes. In conclusion, the combined effects of anemia and CKD on outcomes post-PCI appear to be worse than either of their effects individually.

摘要

很少有研究评估过同时患有贫血(女性血红蛋白<12g/dl;男性<13g/dl)和慢性肾脏病(CKD,估计肾小球滤过率<60ml/min/1.73m)的经皮冠状动脉介入治疗(PCI)患者的预后。我们纳入了 2010 年至 2018 年在我们的医疗体系中接受 PCI 的患有冠状动脉疾病的患者(n=10756),排除了患有 ST 段抬高型心肌梗死或休克的患者。我们评估了贫血和 CKD 对结局的单独和联合影响。在同时患有贫血和 CKD 的患者中,五年死亡率最高,而在既不患有贫血也不患有 CKD 的患者中,五年死亡率最低。经过多变量分析,以既不患有贫血也不患有 CKD 的组作为参照,与无贫血且无 CKD 的患者相比,单纯贫血患者的死亡风险调整后危险比为 1.68(95%置信区间[CI]为 1.45 至 1.95,p<0.001),单纯 CKD 患者的危险比为 1.33(95%CI 为 1.15 至 1.53,p<0.001),同时患有贫血和 CKD 的患者的危险比为 2.83(95%CI 为 2.49 至 3.22,p<0.001)。关于再入院和再介入,观察到类似的趋势,同时患有 CKD 和贫血的患者这些结局的风险最高。总之,贫血和 CKD 对 PCI 后结局的联合影响似乎比它们各自的影响更差。

相似文献

1
Impact of Chronic Kidney Disease and Anemia on Outcomes After Percutaneous Coronary Revascularization.慢性肾脏病和贫血对经皮冠状动脉血运重建术后结局的影响。
Am J Cardiol. 2019 Sep 15;124(6):851-856. doi: 10.1016/j.amjcard.2019.06.001. Epub 2019 Jun 11.
2
Chronic kidney disease and diabetes associated with long-term outcomes in patients receiving percutaneous coronary intervention.慢性肾脏病和糖尿病与接受经皮冠状动脉介入治疗患者的长期预后相关。
BMC Cardiovasc Disord. 2017 Sep 11;17(1):242. doi: 10.1186/s12872-017-0673-4.
3
Prognostic impact of chronic kidney disease and anemia at admission on in-hospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction.急性心肌梗死直接经皮冠状动脉介入治疗入院时慢性肾脏病和贫血对住院结局的预后影响
Int Heart J. 2014;55(4):301-6. doi: 10.1536/ihj.13-367. Epub 2014 Jun 2.
4
Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial.左主干血运重建经皮冠状动脉介入治疗或冠状动脉旁路移植术治疗慢性肾脏病患者: EXCEL 试验。
J Am Coll Cardiol. 2018 Aug 14;72(7):754-765. doi: 10.1016/j.jacc.2018.05.057.
5
Five-year mortality outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention.接受经皮冠状动脉介入治疗的慢性肾脏病患者的五年死亡率结局
Catheter Cardiovasc Interv. 2017 Mar 1;89(4):E124-E132. doi: 10.1002/ccd.26664. Epub 2016 Aug 13.
6
In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease.慢性肾脏病患者慢性完全闭塞性经皮冠状动脉介入治疗的院内结局
J Invasive Cardiol. 2018 Nov;30(11):E113-E121. Epub 2018 Sep 15.
7
Outcomes of STEMI patients with chronic kidney disease treated with percutaneous coronary intervention: the Malaysian National Cardiovascular Disease Database - Percutaneous Coronary Intervention (NCVD-PCI) registry data from 2007 to 2014.接受经皮冠状动脉介入治疗的慢性肾脏病ST段抬高型心肌梗死患者的预后:马来西亚国家心血管疾病数据库——2007年至2014年经皮冠状动脉介入治疗(NCVD-PCI)注册数据。
BMC Cardiovasc Disord. 2018 Sep 24;18(1):184. doi: 10.1186/s12872-018-0919-9.
8
Impact of Chronic Kidney Disease on Cardiovascular and Renal Events in Patients Undergoing Percutaneous Coronary Intervention with Everolimus-Eluting Stent: Risk Stratification with C-Reactive Protein.经皮冠状动脉介入治疗中应用依维莫司洗脱支架的患者中慢性肾脏病对心血管和肾脏事件的影响:C 反应蛋白的风险分层。
Cardiorenal Med. 2018;8(2):151-159. doi: 10.1159/000486971. Epub 2018 Mar 27.
9
Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention.肾功能不全严重程度对行经皮冠状动脉介入治疗患者住院死亡率相关因素的影响。
Catheter Cardiovasc Interv. 2012 Sep 1;80(3):352-7. doi: 10.1002/ccd.23394. Epub 2012 May 4.
10
Predictors of outcomes of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with chronic kidney disease.慢性肾脏病患者经皮冠状动脉介入治疗后对比剂诱导的急性肾损伤结局的预测因素
Am J Cardiol. 2014 Dec 15;114(12):1830-5. doi: 10.1016/j.amjcard.2014.09.022. Epub 2014 Sep 28.

引用本文的文献

1
Dual impact of anaemia and chronic kidney disease on postpercutaneous coronary intervention outcomes: insights from the Japanese nationwide registry.贫血和慢性肾脏病对经皮冠状动脉介入治疗术后结局的双重影响:来自日本全国性注册研究的见解
Open Heart. 2025 Jun 3;12(1):e003146. doi: 10.1136/openhrt-2024-003146.
2
Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.经皮冠状动脉介入治疗后基于 CYP2C19 基因型指导的 P2Y 抑制剂治疗剂量递增在慢性肾脏病患者中的疗效和安全性:TAILOR-PCI 研究的事后分析。
Cardiovasc Drugs Ther. 2024 Jun;38(3):447-457. doi: 10.1007/s10557-022-07392-2. Epub 2022 Nov 29.
3
Development and Validation of a Predictive Model for Chronic Kidney Disease After Percutaneous Coronary Intervention in Chinese.
中文经皮冠状动脉介入治疗后慢性肾脏病的预测模型的建立和验证。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296211069998. doi: 10.1177/10760296211069998.
4
Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach.慢性肾脏病中的冠状动脉疾病:需要基于心肾团队的方法。
Eur Cardiol. 2021 Dec 7;16:e48. doi: 10.15420/ecr.2021.30. eCollection 2021 Feb.
5
Coronary angiography in patients with acute heart failure: from the KCHF registry.急性心力衰竭患者的冠状动脉造影:来自 KCHF 注册研究。
ESC Heart Fail. 2022 Feb;9(1):531-544. doi: 10.1002/ehf2.13716. Epub 2021 Nov 21.
6
Prophylactic dialysis improves short-term clinical outcome in patients with non-dialysis-dependent chronic kidney disease undergoing cardiac surgery: a meta-analysis of randomized controlled trials.预防性透析可改善非透析依赖性慢性肾脏病患者心脏手术后的短期临床结局:一项随机对照试验的荟萃分析。
Coron Artery Dis. 2022 Jan 1;31(1):e73-e79. doi: 10.1097/MCA.0000000000001080.
7
Different Lipid Parameters in Predicting Clinical Outcomes in Chinese Statin-Naïve Patients After Coronary Stent Implantation.不同血脂参数对中国初治他汀类药物患者冠状动脉支架植入术后临床结局的预测作用
Front Cardiovasc Med. 2021 Mar 16;8:638663. doi: 10.3389/fcvm.2021.638663. eCollection 2021.
8
Resveratrol Reduces Kidney Injury in a Rat Model of Uremia and is Associated with Increased Expression of Heat Shock Protein 70 (Hsp70).白藜芦醇可减轻尿毒症大鼠的肾损伤,其作用与热休克蛋白 70(Hsp70)表达增加有关。
Med Sci Monit. 2020 Feb 10;26:e919086. doi: 10.12659/MSM.919086.
9
12-Month clinical outcomes of amphilimus drug eluting stents in an all-comers South-East Asian registry.东南亚全人群登记研究中安普利莫司药物洗脱支架的12个月临床结局
Int J Cardiol Heart Vasc. 2020 Jan 23;26:100469. doi: 10.1016/j.ijcha.2020.100469. eCollection 2020 Feb.